Trials / Completed
CompletedNCT01918865
Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS-PTP1BRx | |
| DRUG | Placebo | |
| DRUG | daily OAD (metformin and/or sulfonylurea) |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-10-01
- Completion
- 2015-02-01
- First posted
- 2013-08-08
- Last updated
- 2015-03-03
Locations
21 sites across 3 countries: Argentina, Canada, South Africa
Source: ClinicalTrials.gov record NCT01918865. Inclusion in this directory is not an endorsement.